We are writing to update you in relation to the supply disruption to Becton Dickinson’s (BD) blood specimen collection portfolio, further to our letter sent on 26 August. We appreciate that the supply shortage has been challenging and thank you for your efforts in managing this issue and for your continued collaboration across local, regional and national networks.
Working closely with DHSC, MHRA and NHS Supply Chain, we have secured 9 million BD tubes from US stocks. MHRA has approved these for use in the UK by way of an exceptional use authorisation (EUA).
BD has now completed improvements to its manufacturing facility in the UK and expects its production capacity to recover through September.
These developments, alongside the efforts of NHS staff to manage use, mean that the supply situation is no longer as constrained as when we wrote to you on 26 August. However, the issue is not yet completely resolved.
This alert contains further information and action for providers.